Hepatitis C (HCV)
- HCV therapies for individuals co-infected with HIV who previously failed treatment or is currently receiving treatment for the first time (EXPEDITION-2, A5348).
- Initiating new HIV treatment with Genvoya or Odefsey prior to starting HCV medication (i.e. Harvoni) to evaluate the effectiveness of both therapies (Co-STAR).
- Effectiveness of early treatment of HCV (within the first 6 months of acquiring the infection) with Harvoni in HIV positive individuals (A5327).
- Whether a daily dose of a statin medication (i.e. pitavastatin) lowers the risk of heart-related disease among people living with HIV (REPRIEVE).
- A specialized HIV test that can detect HIV as early as one week after exposure to the virus (The Early Test).
- Whether HIV can be successfully controlled (i.e. undetectable) with fewer than three HIV drugs (using dolutegravir & lamivudine) among people living with HIV and have consistently maintained undetectable viral loads (ASPIRE).
- One strategy on the pathway to possibly curing HIV by activating hidden HIV in the body so that it comes out to places where HIV medications can work to destroy it (Kick and Kill).
- Whether adding maraviroc and/or dolutegravir to a stable ARV regimen will improve one's ability to concentrate, remember, solve problems and make decisions (HAND).
- The effects of a probiotic called Visbiome ES on stomach and intestinal conditions among people living with HIV (A5350).
- Whether HIV can be successfully controlled (i.e. undetectable) using dolutegravir and lamivudine among people living with HIV and have never taken HIV medications (A5353).
Women's Reproductive Health (for HIV-negative individuals)
- HIV prevention methods with HIV-negative cisgender women using Pre-Exposure Prophylaxis (PrEP) and text messaging (AEGiS).
- An investigational drug called Lactin-V that may prevent recurrent bacterial vaginosis or BV (LACTIN-V).
To learn more about these and other current HIV, hepatitis B, hepatitis C, and tuberculosis clinical trials, please call our Screening Coordinator at (619) 543-3196.
Page 'Breadcrumb' Navigation: